Dimension

What they fund

Dimension funds multistage companies operating at the frontiers of science and compute [1]. The firm specifically targets the intersection of technology and life sciences, with a strong emphasis on AI-driven innovation in drug discovery platforms [1]. The firm's high-conviction approach suggests it funds companies with significant potential to transform the trajectory of life on earth [1].

Investment thesis

Dimension is a multistage, research-oriented investment firm partnering with companies at the intersection of technology and life sciences, specifically targeting the convergence of science and compute to transform the trajectory of life on earth [1]. The firm emphasizes AI-driven scientific innovation, particularly within drug discovery platforms, aiming to leverage computational power to accelerate biological breakthroughs [1]. Guided by the ethos to "make no little plans" and "risk too little," Dimension takes a high-conviction approach to backing founders building at the frontiers of science and compute [1].

• Science and Compute Convergence — Dimension partners with companies operating at the frontiers of science and compute, specifically targeting the intersection of technology and life sciences to transform the trajectory of life on earth [1].
• AI-Driven Innovation — The thesis emphasizes AI-driven scientific innovation, particularly within drug discovery platforms, aiming to leverage computational power to accelerate biological breakthroughs [1].
• High-Conviction Risk Taking — The firm’s perspective is guided by the ethos to "make no little plans" and "risk too little," indicating a willingness to back high-stakes, high-reward scientific ventures [1].

Credibility: The firm's own website explicitly outlines its focus on the convergence of science and compute, its emphasis on AI-driven innovation in drug discovery, and its high-conviction risk-taking ethos [1].

Value add

Dimension offers research-oriented support, leveraging its team's expertise in science and compute to help portfolio companies navigate complex scientific and technological landscapes. The firm's focus on AI-driven innovation suggests it can provide valuable insights and connections in the drug discovery space. Fit verdict: Dimension is a strong fit for founders building at the intersection of science and compute, particularly in drug discovery. Founder diligence script: 1. How does Dimension's research-oriented approach translate into tangible support for my company? 2. What specific expertise does Dimension bring to the drug discovery space? 3. How does Dimension's high-conviction risk-taking ethos align with my company's growth trajectory?

Portfolio focus

The firm's focus is described as companies at the intersection of science and compute, particularly in drug discovery platforms [1].

Notable investments & exits

• Portfolio Count — The firm currently reports a portfolio count of 1 active investment [1].
• Notable Exit — Michibiku is identified as a notable exit for the firm [1].
• Co-Investors — The firm has partnered with prominent investors including Accel, Bessemer Venture Partners, Notion Capital, and Balderton Capital on various deals [1].

Strategic implications

Dimension's focus on the convergence of science and compute positions it to capitalize on the growing intersection of AI and life sciences. The firm's high-conviction risk-taking ethos suggests it is well-positioned to back breakthrough ventures that other investors may shy away from. Dimension's research-oriented approach could provide a significant competitive advantage in identifying and supporting early-stage scientific ventures.

Where they could go further

Dimension could benefit from building a more robust network of industry experts and advisors to support its portfolio companies. The firm could enhance its value proposition by offering more hands-on support in areas such as regulatory strategy and commercialization. Dimension could explore opportunities to partner with other firms that share its focus on science and compute, thereby expanding its reach and impact.